About Us
We are striving to extend survival in some of the most aggressive forms of cancer.
In 2000, Yoram Palti, our founder and professor emeritus of physiology and biophysics at the Technion — Israel Institute of Technology, sought to leverage his expertise in biophysics to develop a new way to treat solid tumor cancers that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies.
He set up a laboratory in his basement to explore the potential of electric fields as a treatment for solid tumors.
Professor Palti founded Novocure to provide patients with a new cancer treatment based on his hypothesis, since proven, that alternating electric fields, when applied at specific frequencies, can disrupt cancer cell division.
This innovative treatment, Tumor Treating Fields, is a completely different approach to cancer therapy.
“Nobody understood what I was doing,” Professor Palti said of his early development of Tumor Treating Fields.
Palti’s initial research from his basement laboratory evolved to become Novocure – an international oncology company with more than 1,000 employees and operations in North America, Europe, the Middle East and Asia.
Our company began with a patient-forward approach that continues to drive our mission today. With more than 20 years of research and many significant milestones, we believe we are only beginning.
In 2000, Yoram Palti, our founder and professor emeritus of physiology and biophysics at the Technion — Israel Institute of Technology, sought to leverage his expertise in biophysics to develop a new way to treat solid tumor cancers that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies.
He set up a laboratory in his basement to explore the potential of electric fields as a treatment for solid tumors.
Professor Palti founded Novocure to provide patients with a new cancer treatment based on his hypothesis, since proven, that alternating electric fields, when applied at specific frequencies, can disrupt cancer cell division.
This innovative treatment, Tumor Treating Fields, is a completely different approach to cancer therapy.
“Nobody understood what I was doing,” Professor Palti said of his early development of Tumor Treating Fields.
Palti’s initial research from his basement laboratory evolved to become Novocure – an international oncology company with more than 1,000 employees and operations in North America, Europe, the Middle East and Asia.
Our company began with a patient-forward approach that continues to drive our mission today. With more than 20 years of research and many significant milestones, we believe we are only beginning.